Please assess the completion status of the following clinical trial:

Trial Title: Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Myocardial infarction with evidence of significant myocardial necrosis defined as a rise in creatinine kinase \>800 U/l and a troponin T-level (or troponin I-level) \>10x upper limit of normal (ULN). In addition at least 1 of the following criteria must be the met:~   * Symptoms of ischemia~  * ECG (electrocardiogram) changes indicative of new ischemia (new ST-T changes or new LBBB)~  * Imaging evidence of new regional wall motion abnormality~2. 18 - 80 years of age~3. Informed consent has to be given in written form~4. estimated glomerular filtration rate (eGFR) \> 45 ml/min/1.73m2~5. Blood pressure before first drug dosing: Riva Rocci (RR) systolic \>110 mmHg~6. Blood pressure before first drug dosing: Riva Rocci (RR) diastolic \>70 mmHg~7. ≤72h after myocardial infarction (after the performance of a coronary angiography)~Exclusion Criteria:~1. Any other form of diabetes mellitus than type 2 diabetes mellitus, history of diabetic ketoacidosis~2. Blood potential hydrogen (pH) \< 7,32~3. Known allergy to SGLT-2 inhibitors~4. Hemodynamic instability as defined by intravenous administration of catecholamine, calcium sensitizers or phosphodiesterase inhibitors~5. \>1 episode of severe hypoglycemia within the last 6 months and treatment with insulin or sulfonylurea~6. Females of childbearing potential without adequate contraceptive methods (i.e. sterilization, intrauterine device, vasectomized partner; or medical history of hysterectomy)~7. Acute symptomatic urinary tract infection (UTI) or genital infection~8. Patients currently being treated with any SGLT-2 inhibitor or having received treatment with any SGLT-2 inhibitor within the 4 weeks prior to the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: ACTIVE_COMPARATOR): The subjects will receive Empagliflozin 10mg.
- Placebo Oral Tablet (Type: PLACEBO_COMPARATOR): The subjects will receive placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).